ReviewAutoimmunity reviews2009
Therapeutic potential of CD8+ cytotoxic T lymphocytes in SLE.
Review in Autoimmunity reviews, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Differential impact of environmental factors on systemic and localized autoimmunity.Frontiers in immunology · 2023Review
- CD8Rheumatology and immunology research · 2021Review
- Gut Microbiota and Bacterial DNA Suppress Autoimmunity by Stimulating Regulatory B Cells in a Murine Model of Lupus.Frontiers in immunology · 2020Article
- Both perforin and FasL are required for optimal CD8 T cell control of autoreactive B cells and autoantibody production in parent-into-F1 lupus mice.Clinical immunology (Orlando, Fla.) · 2018Article
- Prophylactic and Therapeutic Effects of Interleukin-2 (IL-2)/Anti-IL-2 Complexes in Systemic Lupus Erythematosus-Like Chronic Graft-Versus-Host Disease.Frontiers in immunology · 2018Article
- Signaling Lymphocytic Activation Molecule Family Member 7 Engagement Restores Defective Effector CD8+ T Cell Function in Systemic Lupus Erythematosus.Arthritis & rheumatology (Hoboken, N.J.) · 2017Article
- Article
- Low-Dose IL-2 in the Treatment of Lupus.Current rheumatology reports · 2016Review
- Intrinsic Differences in Donor CD4 T Cell IL-2 Production Influence Severity of Parent-into-F1 Murine Lupus by Skewing the Immune Response Either toward Help for B Cells and a Sustained Autoantibody Response or toward Help for CD8 T Cells and a Downregulatory Th1 Response.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
- IL-2 protects lupus-prone mice from multiple end-organ damage by limiting CD4-CD8- IL-17-producing T cells.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- Class I and II histone deacetylase inhibition by ITF2357 reduces SLE pathogenesis in vivo.Clinical immunology (Orlando, Fla.) · 2014Article
- In vivo maturation of allo-specific CD8 CTL and prevention of lupus-like graft-versus-host disease is critically dependent on T cell signaling through the TNF p75 receptor but not the TNF p55 receptor.Journal of immunology (Baltimore, Md. : 1950) · 2013Article
- T cells, murine chronic graft-versus-host disease and autoimmunity.Journal of autoimmunity · 2012Review
- Genes, tolerance and systemic autoimmunity.Autoimmunity reviews · 2012Review
- Immunodeficiency and autoimmunity: lessons from systemic lupus erythematosus.Trends in molecular medicine · 2012Review
- Pre-clinical screening of immunomodulatory compounds using the parent-into-F1 model.Clinical immunology (Orlando, Fla.) · 2011Article
- Donor CD8 T cells and IFN-gamma are critical for sex-based differences in donor CD4 T cell engraftment and lupus-like phenotype in short-term chronic graft-versus-host disease mice.Journal of immunology (Baltimore, Md. : 1950) · 2011Article
- Implications of the parent-into-F1 model for human lupus pathogenesis: roles for cytotoxic T lymphocytes and viral pathogens.Current opinion in rheumatology · 2010Review
- Donor CD8 T cell activation is critical for greater renal disease severity in female chronic graft-vs.-host mice and is associated with increased splenic ICOS(hi) host CD4 T cells and IL-21 expression.Clinical immunology (Orlando, Fla.) · 2010Article
- Advances in lupus stemming from the parent-into-F1 model.Trends in immunology · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Recent evidence supports the idea that following a break in tolerance, CD8 cytotoxic T lymphocytes (CTL) may be an important but unrecognized mechanism for limiting expansion of autoreactive B cells. Failure of this mechanism could allow persistence of CD4 T cell driven polyclonal B cell activation resulting in clinical lupus. Although CD8 CTL failure may occur early in disease, work in mice supports the concept that therapeutic CTL enhancement may be both practical and beneficial in lupus. Devising such therapy for humans will first require an understanding of the in vivo mechanisms critical in CTL expansion and down regulation, particularly in the lupus setting which may differ from CTL generation in other clinical settings (e.g. tumors, infections).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.